Applied dna and alphazyme conclude linea(tm) rnap manufacturing scale-up project, deliver substantial improvement in linea(tm) ivt platform economics

- project results in over 70% reduction in linea rnap manufacturing cost to yield a material improvement in linea ivt platform profitability - - applied dna secures commercial linea rnap quantity sufficient to support anticipated near-term demand - stony brook, ny and jupiter, fl / accesswire / june 20, 2024 / applied dna sciences, inc. (nasdaq:apdn) (applied dna), a leader in pcr-based dna technologies, and alphazyme llc (alphazyme), a maravai lifesciences company (nasdaq:mrvi) and global provider of specialty enzymes used in the life sciences sector, announced the successful conclusion of the companies' previously announced linea™ rnap manufacturing scale-up agreement. the joint process development project resulted in an over 70% reduction in linea rnap manufacturing costs and the manufacture of a quantity of linea rnap sufficient to support applied dna's anticipated near-term demand for critical starting material for mrna production.
DNA Ratings Summary
DNA Quant Ranking